Clinical Trials Logo

Glaucoma, Angle-Closure clinical trials

View clinical trials related to Glaucoma, Angle-Closure.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05127525 Terminated - Clinical trials for Diabetic Macular Edema

EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)

CLEAN
Start date: November 15, 2021
Phase: Phase 3
Study type: Interventional

This is a randomized, double-masked, multicenter, study to evaluate the efficacy, safety, and tolerability of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections. The study will be conducted in up to 30 centers in the United States (US).

NCT ID: NCT01301378 Terminated - Clinical trials for Primary Open Angle Glaucoma

Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube

Start date: August 2010
Phase: N/A
Study type: Interventional

The investigators hypothesize that KeraSys is a safe as Tutoplast to cover the tube of the Molteno 3 glaucoma drainage device during surgery

NCT ID: NCT01151904 Terminated - Clinical trials for Glaucoma, Angle-Closure

Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients

Start date: November 2009
Phase: Phase 4
Study type: Interventional

This study will evaluate the safety and efficacy of patients switched from latanoprost monotherapy to a combination therapy of latanoprost with COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) for chronic angle closure glaucoma.

NCT ID: NCT00758342 Terminated - Clinical trials for Intraocular Pressure

Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)

Start date: May 2006
Phase: Phase 4
Study type: Interventional

To evaluate the IOP (Intraocular Pressure) lowering efficacy and safety of Brinzolamide 1.0% (Azopt), dosed twice daily as adjunctive therapy in patients treated with Travoprost 0.004% (Travatan) once daily. The study is double masked. The patients will receive either treatment for 12 weeks.